Nothing Special   »   [go: up one dir, main page]

CY2083B1 - Treatment of cognitive disorders - Google Patents

Treatment of cognitive disorders

Info

Publication number
CY2083B1
CY2083B1 CY9802083A CY9802083A CY2083B1 CY 2083 B1 CY2083 B1 CY 2083B1 CY 9802083 A CY9802083 A CY 9802083A CY 9802083 A CY9802083 A CY 9802083A CY 2083 B1 CY2083 B1 CY 2083B1
Authority
CY
Cyprus
Prior art keywords
treatment
cognitive disorders
patient
compound
formula
Prior art date
Application number
CY9802083A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CY2083B1 publication Critical patent/CY2083B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processing Of Meat And Fish (AREA)
CY9802083A 1991-03-01 1998-10-16 Treatment of cognitive disorders CY2083B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK036291A DK36291D0 (da) 1991-03-01 1991-03-01 Anvendelse af piperidylsubstituerede indolderivater til behandling af kognitive lidelser
PCT/DK1992/000063 WO1992015303A1 (en) 1991-03-01 1992-02-28 Treatment of cognitive disorders

Publications (1)

Publication Number Publication Date
CY2083B1 true CY2083B1 (en) 1998-10-16

Family

ID=8092662

Family Applications (1)

Application Number Title Priority Date Filing Date
CY9802083A CY2083B1 (en) 1991-03-01 1998-10-16 Treatment of cognitive disorders

Country Status (17)

Country Link
US (1) US5444073A (de)
EP (1) EP0575429B1 (de)
JP (1) JP3108434B2 (de)
KR (1) KR0183424B1 (de)
AT (1) ATE131055T1 (de)
AU (1) AU663699B2 (de)
CA (1) CA2105385C (de)
CY (1) CY2083B1 (de)
DE (1) DE69206607T2 (de)
DK (2) DK36291D0 (de)
HK (1) HK1003560A1 (de)
IE (1) IE70600B1 (de)
IL (1) IL101102A (de)
NO (1) NO307406B1 (de)
NZ (1) NZ241800A (de)
WO (1) WO1992015303A1 (de)
ZA (1) ZA921462B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
US6489341B1 (en) 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
WO2004017973A1 (ja) 2002-08-22 2004-03-04 Sumitomo Pharmaceuticals Company, Limited 統合失調症治療剤
CN1826338B (zh) 2003-06-23 2011-07-13 大日本住友制药株式会社 老年性痴呆症治疗药
EP2357474A1 (de) 2004-02-20 2011-08-17 Dainippon Sumitomo Pharma Co., Ltd. Lurasidon zur Verwendung in der Behandlung von Gedächtnis- oder Lernstörungen bei Schizophrenie
US20070212412A1 (en) * 2005-09-08 2007-09-13 H. Lundbeck A/S Stable solid formulation of sertindole
TW200821296A (en) * 2006-06-01 2008-05-16 Lundbeck & Co As H Use of sertindole for the preventive treatment of suicidal behaviour
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48508A (en) * 1974-12-09 1979-10-31 Roussel Uclaf Pharmaceutical compositions comprising piperidylindole derivatives
FR2362628A1 (fr) * 1976-08-26 1978-03-24 Roussel Uclaf Nouveaux derives du piperidyl-indole et leurs sels, procede de preparation et application a titre de medicaments
SE8004129L (sv) * 1979-07-13 1981-01-14 Roussel Uclaf Nya tetrahydropyridin-4-yl-indolderivat samt salter derav, framstellning och anvendning derav sasom lekemedel samt kompositioner innehallande dessa foreningar
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8704572D0 (en) * 1987-02-26 1987-04-01 Lundbeck & Co As H Organic compounds
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater

Also Published As

Publication number Publication date
NO933091L (no) 1993-11-01
JP3108434B2 (ja) 2000-11-13
EP0575429A1 (de) 1993-12-29
ZA921462B (en) 1992-11-25
IL101102A (en) 1996-03-31
NZ241800A (en) 1997-03-24
ATE131055T1 (de) 1995-12-15
US5444073A (en) 1995-08-22
KR930702978A (ko) 1993-11-29
IE70600B1 (en) 1996-12-11
DK36291D0 (da) 1991-03-01
AU1370792A (en) 1992-10-06
EP0575429B1 (de) 1995-12-06
IE920572A1 (en) 1992-09-09
HK1003560A1 (en) 1998-10-30
DE69206607D1 (de) 1996-01-18
JPH06504787A (ja) 1994-06-02
CA2105385A1 (en) 1992-09-02
CA2105385C (en) 2000-08-15
AU663699B2 (en) 1995-10-19
NO933091D0 (no) 1993-08-31
DE69206607T2 (de) 1996-05-15
DK0575429T3 (da) 1996-04-22
IL101102A0 (en) 1992-11-15
KR0183424B1 (ko) 1999-05-01
WO1992015303A1 (en) 1992-09-17
NO307406B1 (no) 2000-04-03

Similar Documents

Publication Publication Date Title
MY127946A (en) Therapeutic formulation for administering tolterodine with controlled release
AU4950096A (en) Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
CA2133998A1 (en) Treatment of macular degeneration
EP0376899A3 (de) Verwendung von L-Carnitinderivaten zur Herstellung eines Arzneimittels zur therapeutischen Behandlung von peripheren Neuropathien
CY2083B1 (en) Treatment of cognitive disorders
ES8605507A1 (es) Un compuesto de 3-indolcarboxamida
ZA922910B (en) Heterocylic pharmaceutical compounds preparation and use
ZA887410B (en) Polyamine derivatives as antineoplastic agents
WO2003013424A3 (en) Use of r-nsaid compounds for anti-hiv treatment
ES8103071A1 (es) Procedimiento de preparacion de nuevos derivados aminicos del benzotiazol
MY104521A (en) Treatment of depression.
AU670491C (en) Pharmaceutical for the treatment of skin disorders
MY133438A (en) Morpholinobenzamide salts
GR3019970T3 (en) Pharmaceutical compositions for use in treating aids
EP0642338A1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit.
HU9203052D0 (en) Method for treatment of hypertension
ZA961795B (en) Pharmaceuticals